Medtronic v. Teleflex Innovations: Federal Circuit Rules on Coaxial Guide Catheter Patents
Medtronic, Inc. and Medtronic Vascular, Inc. challenged the patentability of five Teleflex Innovations coaxial guide catheter patents — including four reissue patents — before the Federal Circuit. The appeal ran 602 days before closing in May 2023, with the docket recording both an 'AFFIRMED' order and a recorded basis of termination of 'Appeal Dismissed'.
Medtronic's Five-Patent Federal Circuit Challenge to Teleflex's Catheter IP
On September 29, 2021, Medtronic, Inc. and Medtronic Vascular, Inc. filed Federal Circuit appeal No. 21-2365 against Teleflex Innovations, S.A.R.L., challenging the patentability of five patents covering coaxial guide catheters used in interventional cardiology procedures. The asserted patents comprise four reissue patents — USRE045380E, USRE045760E, USRE045776E, and USRE047379E — and one utility patent, US8048032B2, suggesting the portfolio had already undergone post-grant correction proceedings before this appeal.
The case closed on May 24, 2023, after 602 days. The recorded basis of termination is 'Appeal Dismissed'; the docket order states 'THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED'. These two characterisations are each reported here as they appear in the record — the specific procedural basis for any divergence between them is not disclosed in the available record. The verdict cause is identified as an invalidity/cancellation action on the ground of patentability.
The 602-day duration is consistent with contested Federal Circuit patent appeals involving multiple reissue patents, which typically require more complex briefing on claim scope and reissue propriety. Why Medtronic pursued challenge across five related catheter patents simultaneously — rather than sequentially — suggests a coordinated invalidity strategy. The specific outcome terms, any remand instructions, and cost allocations are not disclosed in the available public record.
See Complete Case & Patent Analysis →Filing to Appeal Dismissed in 602 days
602 days from filing to close — a Federal Circuit appeal of above-average duration
USRE045380E and four further patents — coaxial guide catheter technology
Medical device companies developing coaxial guide catheters, guide catheter extensions, or related interventional cardiology access systems should prioritise freedom-to-operate analysis against all five patents in this Teleflex portfolio. The survival of the portfolio through a Medtronic-led Federal Circuit invalidity challenge raises the practical enforceability of these claims. Any product that seats or tracks through a guide catheter in a coronary context is potentially within the risk perimeter of this family.
Official order — verbatim text
The docket order states 'ORDERED AND ADJUDGED: AFFIRMED', which at the Federal Circuit level would indicate the reviewing panel found no reversible error in the tribunal below and that the decision stands. The recorded basis of termination is separately listed as 'Appeal Dismissed'. Both characterisations are reported as they appear in the available record; the specific procedural basis for any divergence between them is not disclosed.
Appeal Dismissed / Affirmed: what the Federal Circuit ruling means for both parties
Two recorded characterisations: Appeal Dismissed and AFFIRMED
The recorded basis of termination for this Federal Circuit appeal is 'Appeal Dismissed'. The docket order separately states 'ORDERED AND ADJUDGED: AFFIRMED'. Each characterisation is reported as it appears in the available record. An affirmance at the Federal Circuit means the reviewing court found no reversible error in the decision below; a dismissal typically ends the appeal without a merits ruling. The specific procedural basis for any divergence is not disclosed in the public record.
Dual characterisation on recordTeleflex's catheter patent portfolio survives Medtronic's challenge
Regardless of which characterisation governs, the practical effect for Teleflex Innovations is that Medtronic's Federal Circuit challenge to all five coaxial guide catheter patents — including four reissue patents — did not result in invalidation at this appellate stage. The patents remain in force on the basis of the public record available here, preserving Teleflex's enforcement position in interventional cardiology.
Portfolio survives appealMedtronic's invalidity campaign stalls at the Federal Circuit
Medtronic and Medtronic Vascular's coordinated challenge to five Teleflex catheter patents did not achieve invalidation at this appellate level. Whether the case was dismissed on procedural grounds or affirmed on the merits, Medtronic's options for further Federal Circuit review at this level are exhausted. Any further challenge would require distinct proceedings — the specific avenues remaining are not disclosed in the available record.
Appellate challenge unsuccessfulCoaxial guide catheter IP remains a contested competitive battleground
The survival of five Teleflex reissue and utility patents covering coaxial guide catheter technology for interventional cardiology signals continued IP risk for competitors in this space. Medical device companies developing or commercialising guide catheter extensions and coaxial catheter systems should treat this portfolio as active and enforceable. Freedom-to-operate analysis against the Teleflex catheter patent family is advisable for any product in this category.
Active enforcement risk remainsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Medtronic, Inc. | Company | /Search in Eureka ↗ |
| Co-Plaintiff | Medtronic Vascular, Inc. | Company | Search in Eureka ↗ |
| Defendant | Teleflex Innovations, S.A.R.L. | Individual | /Search in Eureka ↗ |
| Plaintiff counsel | Cyrus Alcorn Morton | Attorney | Counsel for Medtronic, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Robins & Kaplan | Law Firm | Representing Medtronic, Inc.Search in Eureka ↗ |
| Defendant counsel | J. Derek Vandenburgh | Attorney | Counsel for Teleflex Innovations, S.A.R.L.Search in Eureka ↗ |
| Defendant law firm | Carlson, Caspers, Vandenburgh & Lindquist, PA | Law Firm | Representing Teleflex Innovations, S.A.R.L.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
R&D signals in the coaxial guide catheter and interventional cardiology space
Forward-looking patent and innovation intelligence derived from the Medtronic v. Teleflex Federal Circuit appeal — for R&D teams and IP strategists in the interventional cardiology device sector.
Teleflex's reissue-heavy catheter portfolio signals ongoing claim expansion
Four of the five patents in this dispute are reissue patents, suggesting Teleflex has repeatedly revisited and potentially broadened its coaxial guide catheter claims post-grant. Tracking Teleflex Innovations' reissue filing activity and continuation strategy in the catheter space can reveal where claim scope is being actively extended — and where new infringement risk may be emerging for competitors.
Reissue claim expansion riskFiling trends in coaxial catheter and guide extension technology
Interventional cardiology catheter technology — particularly guide catheter extensions and coaxial delivery systems — has seen sustained patent filing activity from major device makers. Mapping filing trends across this space can identify which assignees are building out competing portfolios, where claim density is highest, and where whitespace exists for differentiated catheter architectures that avoid the Teleflex claim perimeter.
Catheter IP filing trendsMedtronic's catheter patent portfolio after a failed Federal Circuit challenge
Medtronic's decision to challenge five Teleflex catheter patents simultaneously at the Federal Circuit suggests strategic concern about freedom to operate in this product category. Analysing Medtronic's own guide catheter and interventional access patent portfolio can reveal whether it is building defensive IP to counterbalance the Teleflex portfolio — and where its R&D investment in coaxial catheter design is concentrated.
Medtronic defensive IP activityDesign-around opportunities near the Teleflex coaxial catheter claims
The survival of the Teleflex reissue portfolio narrows the freedom-to-operate landscape for conventional coaxial guide catheter designs. However, adjacent innovation areas — including alternative catheter engagement mechanisms, non-coaxial guide extension architectures, and novel catheter materials — may represent lower-density patent space. Mapping claim boundaries across the Teleflex family can surface concrete design-around trajectories for R&D teams.
Design-around opportunitiesSimilar Federal Circuit appeals involving interventional cardiology device patents
Explore related Federal Circuit invalidity and patentability appeals in the interventional cardiology and guide catheter technology space, including comparable reissue patent challenges.
What this case signals for the interventional cardiology IP landscape
Five catheter patents, a coordinated Federal Circuit challenge, and a dual-characterised outcome: here is what IP teams need to take away.
Reissue patent portfolios amplify appellate complexity and cost
Four of the five patents challenged here are reissue patents — a structure that often signals the patentee has already broadened or corrected claims post-grant. Challengers should expect reissue portfolios to require more intensive briefing on claim scope and reissue propriety, extending Federal Circuit timelines. Factor this into IPR and appeal strategy planning.
Simultaneous multi-patent Federal Circuit appeals carry procedural risk
Medtronic's decision to challenge five related patents in a single appeal is consistent with an efficiency-driven strategy, but the dual-characterised outcome — dismissed and affirmed — suggests procedural complexity that can undermine a consolidated approach. IP teams should model the risk of procedural dismissal alongside merits arguments when bundling related patents in appellate proceedings.
Medtronic v Teleflex — key questions answered
The case closed on May 24, 2023. The recorded basis of termination is 'Appeal Dismissed'. The docket order separately states 'ORDERED AND ADJUDGED: AFFIRMED'. Both characterisations are reported as they appear in the public record; the specific procedural basis for any divergence is not disclosed in the available record.
Five patents covering coaxial guide catheter technology for interventional cardiology: USRE045380E, USRE045760E, USRE045776E, and USRE047379E (reissue patents) and US8048032B2 (utility patent). Four of the five are reissue patents, indicating post-grant claim correction or broadening by Teleflex.
The available record identifies the challenge as an invalidity/cancellation action on the ground of patentability across all five patents. The specific strategic rationale for consolidating five patents in one Federal Circuit appeal is not disclosed in the public record, though it is consistent with a coordinated invalidity strategy targeting a related patent family.
A reissue patent is one where the USPTO has corrected or modified the original grant — often to broaden or clarify claims. Four of the five Teleflex patents at issue here are reissue patents, suggesting active post-grant claim management. This is relevant because reissued claims may have different scope than the originals, affecting both infringement analysis and invalidity arguments.
The Teleflex coaxial guide catheter portfolio — five patents including four reissues — survived Medtronic's Federal Circuit invalidity challenge. For competitors developing guide catheter extensions or coaxial interventional access systems, this outcome signals that the Teleflex portfolio is enforceable and that invalidity arguments at this level were not successful. Freedom-to-operate analysis against this family is advisable for any product in this category.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.